BIS Regular Dividend: BIS began trading ex-dividend on 03/25/15. A $0.00 dividend will be paid to shareholders of record as of 03/27/15.
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index ®.
The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times the inverse (-2x) of the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. It is non-diversified.
Latest BIS News
|1 month||-12.26%|| ||3 years||-59.01%|
|3 months||-31.63%|| ||5 years||--|
|1 year||-63.06%|| ||Since inception||-51.71%|
|Open day’s range||34.24 – 36.53|
|Net asset value (NAV)||32.36 (03/24/2015)|
|Average volume (3 months)||314,938|
Data as of 3:59pm ET, 03/26/2015
Peer Comparisonvs. Trading-inverse equity ETFs
|Performance 5-yr return||--||-30.54%|
|Expense Gross exp ratio||1.45%||0.95%|
|Risk 5 year sharpe ratio||--||-1.10|
|Average market cap||--||--|
|Dividend / Share||--||0.35%|
|SDS ProShares UltraShort S&P500|
|SH ProShares Short S&P500|
|SPXU ProShares UltraPro Short S&P500|
Top 5 Sectors
Top 10 Holdings